Price cuts from manufacturers ensures reimbursement in China

Reports show that global manufacturers of medicines have been prepared to cut drugs prices by 61%, on average, in order to achieve reimbursement in China.

Reuters reported that the National Healthcare Security Administration (NHSA) was able to announce the additional of several high-profile medicines to the list, including Pertuzumab (Roche) and Omalizumab (Novartis) thanks to the reductions, giving China the “lowest prices globally” for the additions.

Reuters said:

“Tumor and diabetes medicines saw an average price cut of about 65%, according to the NHSA.

“Other drugs added included Adalimumab, an arthritis treatment which AbbVie (ABBV.N) sells as Humira, one of the top-selling drugs in the world.”

Find out more here.

Tagged with

Published 2. December 2019 in News